

Hamidreza Montazeri Aliabadi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6373551/publications.pdf>

Version: 2024-02-01

30
papers

1,042
citations

516710

16
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

1527
citing authors

#	ARTICLE	IF	CITATIONS
1	[(WR)8WKÎ²A]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. <i>Cells</i> , 2022, 11, 301.	4.1	8
2	Redox-Responsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2022, 19, 1338-1355.	4.6	6
3	Combinational silencing of components involved in JAK/STAT signaling pathway. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 175, 106233.	4.0	4
4	Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. <i>Frontiers in Nanotechnology</i> , 2021, 3, .	4.8	4
5	Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113836.	5.5	14
6	Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System. <i>Molecular Pharmaceutics</i> , 2021, 18, 986-1002.	4.6	11
7	A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies. <i>Acta Biomaterialia</i> , 2020, 102, 351-366.	8.3	17
8	Prospects for RNAi Therapy of COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 916.	4.1	69
9	Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. <i>Frontiers in Oncology</i> , 2019, 9, 1070.	2.8	9
10	Amphiphilic Peptides for Efficient siRNA Delivery. <i>Polymers</i> , 2019, 11, 703.	4.5	19
11	Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 397-418.	5.0	23
12	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. <i>Acta Biomaterialia</i> , 2018, 66, 294-309.	8.3	31
13	In vitro and ex-vivo evaluation of topical formulations designed to minimize transdermal absorption of Vitamin K1. <i>PLoS ONE</i> , 2018, 13, e0204531.	2.5	4
14	“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway. <i>Frontiers in Oncology</i> , 2018, 8, 287.	2.8	283
15	Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery. <i>ACS Omega</i> , 2017, 2, 6939-6957.	3.5	10
16	Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates. <i>Scientific Reports</i> , 2017, 7, 6093.	3.3	20
17	Alzheimer’s Disease: Dawn of a New Era?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 20, 184.	2.1	13
18	Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models. <i>Scientific Reports</i> , 2016, 6, 23078.	3.3	24

#	ARTICLE	IF	CITATIONS
19	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. <i>Journal of Biomedical Materials Research - Part A</i> , 2016, 104, 3031-3044.	4.0	20
20	Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. <i>Molecular Pharmaceutics</i> , 2016, 13, 4116-4128.	4.6	17
21	Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 14.	4.1	21
22	Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy. <i>Pharmaceutical Research</i> , 2015, 32, 3813-3826.	3.5	14
23	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, 3216-3228.	4.0	22
24	Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. <i>Journal of Controlled Release</i> , 2013, 172, 219-228.	9.9	56
25	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. <i>Journal of Biomedical Materials Research - Part A</i> , 2013, 102, n/a-n/a.	4.0	13
26	Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 33-42.	4.3	33
27	Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. <i>Molecular Pharmaceutics</i> , 2011, 8, 1821-1830.	4.6	61
28	The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporine A: In Vitro and In Vivo Studies. <i>AAPS Journal</i> , 2011, 13, 159-168.	4.4	16
29	Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers. <i>Macromolecular Bioscience</i> , 2011, 11, 662-672.	4.1	77
30	Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. <i>Biomaterials</i> , 2005, 26, 7251-7259.	11.4	123